Analytical Data
-
Gene name
MET
- Application
-
Alternative Names
MET；Hepatocyte growth factor receptor
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P08581
-
Expression Region
956-1390aa
-
AA Sequence
KKRKQIKDLGSELVRYDARVHTPHLDRLVSARSVSPTTEMVSNESVDYRA TFPEDQFPNSSQNGSCRQVQYPLTDMSPILTSGDSDISSPLLQNTVHIDL SALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKI HCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLV VLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDL AARNCMLDEKFTVKVADFGLARNMYDKEYYSVHNKTGAKLPVKWMALESL QTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQP EYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNAT YVNVKCVAPYPSLLSSEDNADDEVDTRPASFWETS
-
Molecular Weight
81 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The MET receptor tyrosine kinase plays a crucial role in various biological processes, including cell growth, survival, and migration. It is activated by its ligand, hepatocyte growth factor (HGF), and is involved in normal physiological functions as well as pathological conditions, particularly in cancer. Abnormal MET signaling is implicated in various malignancies, where it can lead to increased tumor growth, metastasis, and resistance to therapies. As a result, MET has emerged as a promising target for cancer therapy, particularly in tumors where MET signaling is dysregulated. Researchers have focused on developing MET-targeted therapies, including small molecule inhibitors and monoclonal antibodies, to inhibit its activity. Moreover, the investigation of MET receptor structure and function has led to the design of recombinant MET proteins that can be used to better understand receptor interactions and signaling pathways. These recombinant proteins serve as valuable tools for elucidating the mechanisms of MET-related pathologies and for the screening of therapeutic agents. In addition, understanding the biology of MET and producing robust recombinant MET proteins may facilitate the development of diagnostic and prognostic biomarkers for MET-driven cancers. Thus, ongoing research into MET, including the engineering of its recombinant proteins, holds significant promise for advancing cancer treatment and improving therapeutic outcomes for patients with MET-related malignancies.
